A group of economist has entered the scene within the Supreme Court and the current case made by the Federal Trade Commission against the so-called pay-for-delay deals in which brand-name drug makers pay their generic counterparts to stay off the shelves for some time. An amicus brief was filed last Friday on behalf of the economists arguing that the FTC does not present sufficient economic evidence to back its claims that pay-for-delay deals hurt consumers. Additionally, the economists are claiming the FTC’s definition of pay-for-delay, or reverse payments, is too broad, and that reverse payments are economically the same as other patent settlements in other markets.
Featured News
NBA Teams Up With US Regulator on Prediction Markets
Oct 27, 2026 by
CPI
Intesa Wins ECB Approval for $36 Billion Monte dei Paschi Takeover
Oct 27, 2026 by
CPI
PayPal, Revolut Weigh In as UK Targets Apple’s Tap-to-Pay Rules
Oct 27, 2026 by
CPI
Heineken Ordered to Pay $124 Million in Greek Antitrust Case
Oct 27, 2026 by
CPI
FTC Raises Antitrust Concerns Over Cintas’ $5.5 Billion Deal
Oct 27, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Exclusive Dealing
Oct 25, 2026 by
CPI
Exclusive Dealing Without Exclusivity: Screening Contracts, Loyalty Rebates, and the Limits of Antitrust Tests
Oct 25, 2026 by
David Martimort & Jérôme Pouyet
When Competition for Exclusivity Raises Prices: Rebates, Pricing Rules, and the Insulin Puzzle
Oct 25, 2026 by
Daniel P. O’Brien & Greg Shaffer
Why Leaving the Door Open Can Be (Much) Worse Than Closing It: Share-Based Requirements, Buyer-Specific Costs, and Foreclosure
Oct 25, 2026 by
Zhijun Chen & Greg Shaffer
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI